Skip to content
10-Q

Quarterly Report

Enveric Biosciences, Inc. ENVB

0001493152-26-023353

← back to feed
Filed
May 15, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 13, 2026 3.68M sh
Shares Diluted Q1 2026 · Mar 31, 2026 1.51M sh
Shares Diluted restated Q1 2026 · Mar 31, 2025 149.82K sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$2.26M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$2.39M
Stockholders Equity Q1 2026 · Mar 31, 2026 $5.06M
Stockholders Equity Q1 2026 · Dec 31, 2025 $4.18M
Stockholders Equity Q1 2026 · Mar 31, 2025 $3.92M
Stockholders Equity Q1 2026 · Dec 31, 2024 $1.59M
Current Liabilities Q1 2026 · Mar 31, 2026 $460.68K
Current Liabilities Q1 2026 · Dec 31, 2025 $918.4K
Current Assets Q1 2026 · Mar 31, 2026 $5.38M
Current Assets Q1 2026 · Dec 31, 2025 $4.94M
Total Assets Q1 2026 · Mar 31, 2026 $5.52M
Total Assets Q1 2026 · Dec 31, 2025 $5.1M
Eps Diluted Q1 2026 · Mar 31, 2026 −$1.08
Eps Diluted restated Q1 2026 · Mar 31, 2025 −$14.58
Eps Basic Q1 2026 · Mar 31, 2026 −$1.08
Eps Basic restated Q1 2026 · Mar 31, 2025 −$14.58
Rd Expense Q1 2026 · Mar 31, 2026 $345.97K
Rd Expense Q1 2026 · Mar 31, 2025 $746.37K
Net Income Q1 2026 · Mar 31, 2026 −$1.63M
Net Income Q1 2026 · Mar 31, 2025 −$2.18M
Operating Income Q1 2026 · Mar 31, 2026 −$1.63M
Operating Income Q1 2026 · Mar 31, 2025 −$2.19M